Bristol-Myers Squibb (BMY) Approaches New Downside Target of $30.53 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. Bristol-Myers Squibb has overhead space with shares priced ... |
